Nanomembrane-driven co-elution and integration of active chemotherapeutic and anti-inflammatory agents

International Journal of Nanomedicine

Volumn 3, Issue 4, 2008, Pages 425-433

  Pierstorff, Erik ^a,c   Ho, Dean ^a,b,c  

^a Northwestern University   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Chemotherapy; Co elution; Combinatorial therapy; Drug delivery; Inflammation; Nanomedicine

Indexed keywords

COPOLYMER; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NANOFILM; POLYMETHYLOXAZOLINE POLYDIMETHYLSILOXANE POLYMETHYLOXAZOLINE COPOLYMER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL GROWTH; CONCENTRATION RESPONSE; DNA FRAGMENTATION; DRUG DELIVERY SYSTEM; DRUG MIXTURE; DRUG RELEASE; GENE EXPRESSION; HYDROPHILICITY; HYDROPHOBICITY; LANGMUIR BLODGETT FILM; MACROPHAGE; MOUSE; NANOFABRICATION; NICK END LABELING; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ABSORPTION; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; DRUG CARRIERS; DRUG COMBINATIONS; MACROPHAGES; MATERIALS TESTING; MEMBRANES, ARTIFICIAL; MICE; NANOMEDICINE; NANOSTRUCTURES;

MURINAE;

EID: 69749093489     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ariga K, Nakanishi T, Michinobu T. 2006. Immobilization of biomaterials to nano-assembled films (self-assembled monolayers, Langmuir-Blodgett films, and layer-by-layer assemblies) and their related functions. J Nanosci Nanotechnol, 6:2278-301.
2. Arola OJ, Saraste A, Pulkki K, et al. 2000. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res, 60:1789-92.
3. Chen M, Huang B, Shin E, et al. 2007. Engineering multifunctional biologically-amenable nanomaterials for interfacial therapeutic delivery and substrate-based cellular interrogation. IEEE Proc BIBE, 7:517-23.
4. Chow EK, Pierstorff E, Cheng G, et al. 2008. Copolymeric nanofilm platform for controlled and localized therapeutic delivery. ACS Nano, 2:33-40.
5. Eom YW, Kim MA, Park SS, et al. 2005. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene, 24:4765-77.
6. Gerweck LE, Kozin SV, Stocks SJ. 1999. The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells. Br J Cancer, 79: 838-42.
7. Giri D, Ozen M, Ittmann M. 2001. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol, 159:2159-65.
8. Greish K, Sawa T, Fang J, et al. 2004. SMA-doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours. J Control Release, 97:219-30.
9. Hassan F, Islam S, Mu MM, et al. 2005. Lipopolysaccharide prevents doxorubicin-induced apoptosis in RAW 264.7 macrophage cells by inhibiting p53 activation. Mol Cancer Res, 3:373-9.
10. Hirano T, Nakajima K, Hibi M. 1997. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Cytokine Growth Factor Rev, 8:241-52.
11. Hjelmstrom P. 2001. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J Leukocyte Biol, 69:331-9.
12. Ho D, Chu B, Schmidt J, et al. 2003. Hybrid protein/polymer biomimetic membranes. IEEE Proc Nanotechnol, 3:379-82.
13. Ho D, Chu B, Lee H, et al. 2004. Protein-driven energy transduction across polymeric biomembranes. Nanotechnology, 15:1084-94.
14. Hou M, Chrysis D, Nurmio M, et al. 2005. Doxorubicin induces apoptosis in germ line stem cells in the immature rat testis and amifostine cannot protect against this cytotoxicity. Cancer Res, 65:9999-10005.
15. Huang H, Pierstorff E, Osawa E, et al. 2007. Active nanodiamond hydrogels for chemotherapeutic delivery. Nano Lett, 7:3305-14.
16. Huang H, Pierstorff E, Osawa E, et al. 2008. Protein-mediated assembly of nanodiamond hydrogels into a biocompatible and biofunctional multilayer nanofilm. ACS Nano, 2:203-12.
17. Kang YJ, Sun X, Chen Y, et al. 2002. Inhibition of doxorubicin chronic toxicity in catalase-overexpressing transgenic mouse hearts. Chem Res Toxicol, 15:1-6.
18. Kimura T, Fujita I, Itoh N, et al. 2000. Metallothionein acts as a cytoprotectant against doxorubicin toxicity. Pharm Exp Ther, 292:299-302.
19. Kotamraju S, Konorev EA, Joseph J, et al. 2000. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem, 275:33585-92.
20. Mikosz CA, Brickley DR, Sharkey MS, et al. 2001. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem, 276:16649-54.
21. Moran TJ, Gray S, Mikosz CA, et al. 2000. The glucocorticoid receptor mediates a survival signal in human mammary epithelial cells. Cancer Res, 60:867-72.
22. Nardin C, Winterhalter M, Meier W. 2000. Giant free-standing ABA triblock copolymer membranes. Langmuir, 16:7708-12.
23. Nardin C, Widmer J, Winterhalter M, et al. 2001. Amphiphilic block copolymer nanocontainers as bioreactors. Eur Phys J, E4:403-10.
24. Oishi M, Nakaogami J, Ishii T, et al. 2006. Smart PEGylated gold nanoparticles for the cytoplasmic delivery of siRNA to induce enhanced gene silencing. Chem Lett, 35:1046-7.
25. Olson LE, Bedja D, Alvey SJ, et al. 2003. Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. Cancer Res, 63:6602-6.
26. Palapattu GS, Sutcliffe S, Bastian PJ, et al. 2005. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis, 26:1170-81.
27. Park JI, Lee MG, Cho K, et al. 2003. Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways. Oncogene, 22:4314-32.
28. Pierstorff E, Ho D, 2007. Monitoring, diagnostic, and therapeutic technologies for advanced medicine at the intersection of life science and engineering. J Nanosci Nanotech, 7:2949-68.
29. Pierstorff E, Krucoff M, Ho D. 2008. Apoptosis induction and attenuation of inflammatory gene expression in murine macrophages via multitherapeutic nanomembranes. Nanotechnology, 19:265103-12.
30. Rosi NL, Giljohann DA, Thaxton CS, et al. 2006. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science, 312:1027-30.
31. Siegall CB, Schwab G, Nordan RP, et al. 1990. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res, 50:7786-8.
32. Sridhar R, Dwivedi C, Anderson J, et al. 1992. Effects of verapamil on the acute toxicity of doxorubicin in vivo. J Natl Cancer Inst, 84:1653-60.
33. Taga T, Kishimoto T. 1997. gp130 and the interleukin-6 family of cytokines. Ann Rev Immunol, 15:797-819.
34. Wang GW, Kang YJ. 1999. Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels. Pharm Exp Ther, 288:938-44.
35. Wang S, Konorev EA, Kotamraju S, et al. 2004. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. J Biol Chem, 279:25535-43.
36. Willenberg HS, Päth G, Vögeli TA, et al. 2002. Role of interleukin-6 in stress response in normal and tumorous adrenal cells and during chronic inflammation. Ann N Y Acad Sci, 966:304-14.
37. Wu W, Chaudhuri S, Brickley DR, et al. 2004. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res, 64:1757-64.
38. Yoo HS, Park TG. 2001. Biodegradable polymeric micelles composed of doxombicin conjugated PLGA-PEG block copolymer. J Control Release, 70:63-70.
39. Yoo HS, Park TG. 2004. Folate receptor targeted biodegradable polymeric doxombicin micelles. J Control Release, 96:273-83.